Similar to the breast cancer model, anti-VEGF and imatinib combination markedly induced cellular apoptosis in FGF-2+ fibrosarcomas, which otherwise were completely resistant in their monotherapy settings (Fig. 5d–f). Here, FGF2 is linked to breast carcinoma.